Yield10 Bioscience Interest Expense
Interest Expense of Yield10 Bioscience (YTENQ) as of Sep 19, 2026.
Get this data via API
Financial Data API
Interest Expense
0.00USD
Last updated:
Interest Expense of Yield10 Bioscience is 2026 0.00 USD. Interest Expense of Yield10 Bioscience was 2025 700,000.00 USD. It decreases by % lower compared to the previous year.
The Yield10 Bioscience Interest Expense history
3 Years
10 Years
25 Years
Max
Interest Expense
Date
Interest Expense
Jan 1, 2014
10,000.00 USD
Jan 1, 2018
160,000.00 USD
Jan 1, 2019
9.64 M USD
Jan 1, 2020
-960,000.00 USD
Jan 1, 2021
700,000.00 USD
Jan 1, 2022
0.00 USD
| YEAR | Interest Expense | YoY |
|---|---|---|
| 0.00USD | -100.00% | |
| 700,000.00USD | -172.92% | |
| -960,000.00USD | -109.96% | |
| 9.64 MUSD | +5,925.00% | |
| 160,000.00USD | +1,500.00% | |
| 10,000.00USD | — |
Access this data via the Eulerpool API
Yield10 Bioscience Stock analysis
What does Yield10 Bioscience do? Yield10 Bioscience is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Yield10 Bioscience stock
On Eulerpool you can find the complete historical development of Interest Expense Yield10 Bioscience since 2006 – with annual values, charts, and detailed analysis.
Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.
Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Yield10 Bioscience historically and in real time.
Access this data via the Eulerpool API
Income Statement — Yield10 Bioscience
All Key Metrics — Yield10 Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth